Taking It Out on the Body? A Phenomenological Study of Young Adults’ Gendered Experiences of Depression and Antidepressant Use

In this article, we use in-depth interviews with young adults in Sweden to explore the gendered and embodied experiences of depression and antidepressant use. Building upon previous phenomenological research, we analyse being depressed and on antidepressants as altered embodied states, in which corporealization—experiencing the body as a material object—is central. Feminist interventions by Toril Moi and Iris Marion Young inform our analysis of embodiment as gendered. The bodily facets of depression include the weight of the anxious body in crying and not sleeping, as well as the weakened or distorted relationship between body, mind and world in brooding thoughts and hopelessness. These experiences of corporealization are not expressed in gendered terms but, when acted out in depression, they do appear to be gendered. The female body becomes “the first battleground”—as the socially endorsed object upon which to act destructively. In contrast, male behaviour is not expressed as self-destructive, but projects in the world are emphasized at the cost of (bodily) well-being. Although antidepressants lift the corporeal weight of anxiety and low mood, they install a new, and in some respects more profound, corporealization of the body. This is expressed as feeling and caring less and being like a thing or machine. It can be understood in terms of an increased distance from the world—not articulated in gendered terms. As a way of existing in the world, the medicated state bears strong similarities to the depressed state from which it was originally an effort to escape. Thus, taking medication can be seen as yet another way of acting on the body as object. Furthermore, it could be suggested from our findings that when the body is not felt—when there is a breakdown of the meaningful relationship between the body and the world—the experience is less gendered.     

The Media and the Chemical Imbalance Theory of Depression

The cause of mental disorders such as depression remains unknown. However, the idea that neurotransmitter imbalances cause depression is vigorously promoted by pharmaceutical companies and the psychiatric profession at large. We examine media reports referring to this chemical imbalance theory and ask reporters for evidence supporting their claims. We then report and critique the scientific papers and other confirming evidence offered in response to our questions. Responses were received from multiple sources, including practicing psychiatrists, clients, and a major pharmaceutical company. The evidence offered was not compelling, and several of the cited sources flatly stated that the proposed theory of serotonin imbalance was known to be incorrect. The media can play a positive role in mental health reporting by ensuring that the information reported is congruent with the peer-reviewed scientific literature.

Understanding service users’ and therapists’ experiences of pharmacological treatment for sexual preoccupation and/or hypersexuality in incarcerated sex offenders

This research comprises two qualitative studies understanding the experiences of (1) convicted sex offenders voluntarily receiving pharmacological treatment to reduce sexual preoccupation and (2) therapists working with these offenders. The studies form part of a research programme evaluating the use of pharmacological treatment with sexual offenders. In study one, semi-structured interviews were conducted with 13 sexual offenders receiving selective serotonin reuptake inhibitors. In study two, interviews were conducted with eight intervention staff with varying levels of experience of working with offenders taking anti-libidinals. Thematic analysis was used and in study one, two main themes emerged: (i) the impact of the pharmacological treatment on prisoners’ daily functioning; (ii) barriers to compliance/engagement. In study two, three main themes emerged: (i) offenders’ reluctance to engage with pharmacological treatment; (ii) challenges for therapists; (iii) pharmacology: ‘just another piece of the puzzle’. Findings are discussed in relation to practice and future research.